ISTA Pharma Begins Phase 1/2 Bepotastine Besilate Nasal Spray Study
In the study, ISTA Pharma is expected to evaluate the safety and efficacy of three concentrations of Bepotastine Besilate, dosed twice daily, in an Environmental Exposure Chamber (EEC)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.